Clinical trial
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705
Study timeline
Study start (actual)2022-05-11Date precision: day
Registry last updated2026-09-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
LOXO-783DRUG
FulvestrantDRUG · verified · RxNorm: fulvestrant
ImlunestrantDRUG · verified · RxNorm: imlunestrant
AbemaciclibDRUG · verified · RxNorm: abemaciclib
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
BarcelonaSpain3BostonMassachusetts, United States2DallasTexas, United States2SeoulSouth Korea2MadridSpain2ValenciaSpain2New YorkNew York, United States1HoustonTexas, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05307705 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.